Tyra Biosciences, Inc. (TYRA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $26.18: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Below-average business quality; Negative price momentum.
Tyra Biosciences is a clinical-stage oncology company developing oral FGFR inhibitors using its proprietary SNÅP platform, with lead program oral dabogratinib in Phase 2 trials for LG-UTUC (SURF303), IR NMIBC (SURF302), and achondroplasia (BEACH301). Two additional clinical... Read more
Sell if holding. Engine safety override at $26.18: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 65d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Tyra Biosciences, Inc.
Latest news
- NEWS 12 Health Care Stocks Moving In Monday's After-Market Session — benzinga Jun 1, 2026 neutral
- NEWS This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday — benzinga May 19, 2026 neutral
- NEWS This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday — benzinga May 19, 2026 positive
- NEWS This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday — benzinga May 19, 2026 neutral
- NEWS Wolfe Research Initiates Coverage On Tyra Biosciences with Peer Perform Rating — benzinga May 19, 2026 neutral
Generated 2026-06-09T22:16:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $26.18: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $24.46. Score 5.3/10, moderate confidence.
Take-profit target: $44.50 (+69.9% upside). Prior stop was $24.46. Stop-loss: $24.46.
Quality below floor (1.2 < 4.0).
Tyra Biosciences, Inc. trades at a P/E of N/A (forward -9.4). TrendMatrix value score: 9.0/10. Verdict: Sell.
21 analysts cover TYRA with a consensus score of 4.3/5. Average price target: $51.
What does Tyra Biosciences, Inc. do?Tyra Biosciences is a clinical-stage oncology company developing oral FGFR inhibitors using its proprietary SNÅP...
Tyra Biosciences is a clinical-stage oncology company developing oral FGFR inhibitors using its proprietary SNÅP platform, with lead program oral dabogratinib in Phase 2 trials for LG-UTUC (SURF303), IR NMIBC (SURF302), and achondroplasia (BEACH301). Two additional clinical programs, TYRA-430 (FGFR4, Phase 1 for HCC) and TYRA-200 (FGFR1/2/3, Phase 1 for resistant ICC), round out the pipeline.